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Decreased brain-expressed X-linked 4
(BEX4) expression promotes growth of oral
squamous cell carcinoma
Wei Gao1, John Zeng-Hong Li1,2, Si-Qi Chen1, Chiao-Yun Chu1, Jimmy Yu-Wai Chan1 and Thian-Sze Wong1*
Abstract
Background: Brain-expressed X-linked (BEX) 4 is a member of BEX family. The functional role of BEX4 in oral
squamous cell carcinoma (OSCC) remains unknown.
Methods: Expression level of BEX family members (BEX1-5) in OSCC tissues and the paired normal epithelial were
examined. Functions of epigenetic changes (DNA methylation and histone modifications) on BEX4 suppression in
OSCC were examined by zebularine and trichostatin A (TSA) treatment on OSCC cell lines. Lentivector containing
full-length BEX4 was used to generate OSCC cell lines with stable BEX4 expression. Effects of BEX4 expression on
OSCC proliferation were monitored with xCELLigence RTCA real-time cell analyzer. BEX4-overexpressing CAL27 was
implanted into nude mice to evaluate the effects on tumor growth in vivo. The signaling pathways regulated by
BEX4 in OSCC was explored using human whole-transcript expression microarray.
Results: Among the 5 BEX family members, BEX1 and BEX4 showed significant down-regulation in OSCC (P < 0.001).
BEX3, in comparison, was overexpressed in the primary tumor. BEX4 expression in OSCC cell lines was re-activated after
zebularine and TSA treatment. High BEX4 expression could suppress proliferation of OSCC in vitro. Subcutaneous
tumor volume of BEX4-overexpressing CAL27 was remarkably reduced in nude mice. Microarray experiment showed
that S100A family members (S100A7, S100A7A, S100A8, S100A9 & S100A12) might be the downstream targets of BEX4
in OSCC.
Conclusions: BEX4 functions as tumor suppressor by inhibiting proliferation and growth of oral cancer. Decreased
BEX4 contributes to the increased proliferative propensity of OSCC.
Keywords: Oral cancer, Squamous cell carcinoma, Brain-expressed X-linked family, BEX4, Tumor growth, S100A family
Background
Epithelial cancer derived from the oral mucosa is a com-
mon head and neck cancer [1]. Histologically, oral squa-
mous cell carcinoma (OSCC) is the major subtype
contributing to over 90 % of the cases [2]. Despite the
advances in cancer detection techniques and treatment
methods in the past decade, the incidence of OSCC re-
mains high and the 5-year survival rate of OSCC pa-
tients remains unsatisfactory [3]. OSCC is an aggressive
head and neck cancer due to the rapid proliferative cap-
ability and high invasive nature [4]. The survival rate of
OSCC patients showed close association with the tumor
size [5]. It has been shown that tumor size is an inde-
pendent predictive factor for survival of OSCC patients
[6]. Therefore, a better understanding on the underlying
mechanisms involve in OSCC growth is important to
improve the prognosis of OSCC patients.
Silencing key tumor suppressor genes by epigenetic
mechanisms are essential for the carcinogenic develop-
ment of OSCC. Identifying key methylated genes with
functional implications in the development of OSCC
would be useful in diagnosis and as therapeutic targets
[7]. High-throughput parallel screening using expression
and methylation microarrays had shown that brain-
expressed X-linked (BEX) members were susceptible to* Correspondence: thainsze@gmail.com1Department of Surgery, The University of Hong Kong, Hong Kong SAR,
China
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epigenetic inactivation in OSCC [8]. Human BEX mem-
bers (BEX1, BEX2, BEX3, BEX4, BEX5) are all located
on chromosome Xq22. They are highly conserved genes
among different species (including chimp, mouse, rat,
dog and human) implying their importance in cellular
functions [9]. At present, little is known about the func-
tional implications of BEX family members in the pro-
gression of human malignancies. It has been reported
that BEX family members could regulate cell cycle and
apoptotic signaling [10, 11].
BEX family members displayed distinct tissue distribu-
tion and have varying roles dependent on different cellu-
lar context. Thus, in the present study, we first explored
the expression patterns of the human BEX family mem-
bers in OSCC. Given that BEX4 expression was remark-
ably reduced in our cohort, we hypothesized that BEX4
could possibly play a tumor-suppressing role in OSCC.
Further, whether DNA methylation or chromatin remod-
eling would be a possible cause of BEX4 suppression in
OSCC will also be investigated. The functional role of
BEX4 on tumor growth was examined using OSCC cell
lines and xenograft models. As there was no information
about the functional role of BEX4 in human malignancies,
global gene expression change of BEX4-overexpressing
OSCC cell line will be explored using microarray.
Methods
Cell cultures
Human tongue squamous cell carcinoma cell line CAL27
was obtained from American Type Culture Collection.
Buccal squamous cell carcinoma cell line YD-38 was ob-
tained from Korean cell line bank. Both cell lines were
maintained in RPMI 1640 medium supplemented with
10 % fetal bovine serum, 100 U/ml penicillin and 100 μg/
ml streptomycin. Drug treatment started after cell seeding
for 24 h. For zebularine treatment, the cells were har-
vested after 72 h. For trichostatin A (TSA) treatment, the
cells were harvested after 24 h.
Clinical samples
Sixty-five OSCC and the paired normal tissues were ex-
amined. Tissue were obtained from patients underwent
surgery in Division of Head and Neck, Queen Mary
Hospital, Hong Kong. All the cancer tissues were squa-
mous cell carcinoma. Consent of tissue donation for re-
search purpose was obtained before sample collection.
The study was approved by the ethnic review board of
our institute (registered number: UW12-123).
RNA extraction and real-time quantitative polymerase
chain reaction (qPCR)
Total RNA was extracted using Trizol reagent (Invitro-
gen). First-strand cDNA synthesis was performed using
High Capacity cDNA Reverse Transciption Kit (ABI).
Transcript level was evaluated by qPCR using FastStart
Universal Probe Master (Roche Applied Science) on
LightCycler® 480 (Roche Applied Science). Table 1 listed
the primers and probes used in this study. Reactions were
performed at 95 °C for 10 min followed by 45 cycles of
95 °C for 15 s and 60 °C for 1 min. Expression levels were
evaluated using the comparative threshold cycle methods.
Immunocytochemistry
OSCC cells were seeded on chamber slides and treated
with zebularine and TSA. Cells were fixed with 4 %
paraformaldehyde and permeabilized using 0.2 % Triton
X-100 in PBS. After blocking, cells were incubated with
anti-BEX4 antibodies (Abcam) and CF488-conjugated
secondary antibodies (Biotium). Cells were visualized by
fluorescent microscope (Nikon).
Immunohistochemistry
Tissue samples embedded into paraffin blocks were cut
into 4-μm sections. After deparaffinization and rehydra-
tion, sections were microwaved in 10 mM sodium citrate
buffer for antigen retrieval and stained with anti-BEX4
antibodies (Abcam) at room temperature for 1 h. DAKO
EnVision + System, HRP (DAKO) was used for visualiza-
tion of immunoreaction. Then, sections were stained
with Mayer’s hematoxylin, dehydrated and photographed
under light microscope. BEX4 protein expression level
was graded as low, moderate or high depending on the
staining intensity. Association between BEX4 expression
and the clinicopathological parameters of OSCC patients
was evaluated by Chi-square test or Fisher’s exact test.
Lentivirus vector construction, lentivirus production and
infection
Full-length BEX4 coding sequence was cloned into lenti-
viral expression vector pCDH (System Biosciences) to
generate the BEX4-expressing vector (pCDH-BEX4 vec-
tor). Vector sequences were verified by direct sequencing.
Virus packaging was performed by transient transfection
into 293 T cells using Lipofectamine® 2000 Transfection
Reagent (Invitrogen). OSCC cell lines CAL27 and YD-38
were transduced with medium containing lentivirus.
SiRNA transfection
BEX4 siRNA-1, BEX4 siRNA-2 and negative control
siRNA (QIAGEN) were transfected into OSCC cells using
HiPerFect transfection reagent (QIAGEN) according to
the manufacturer’s protocol. After 72 h, cells were col-
lected and the efficiency of BEX4 silencing was deter-
mined by qPCR and immunocytochemistry.
Western blot
His-tag BEX4 protein was obtained from Novus Biologi-
cals. Protein was extracted from cells using RIPA lysis
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buffer. Protein concentration was measured by BCA pro-
tein assay system (Pierce). Proteins separated by sodium
dodecyl sulphate-poly-acrylamide gel electrophoresis were
transferred to PVDF membranes and incubated with anti-
BEX4 antibodies (Abcam). After incubation with horse-
radish peroxidase-conjugated goat anti-rabbit secondary
antibody, hybridization signals were developed using ECL
Plus Western Blotting Detection Reagents (Amersham
Biosciences).
Real-time proliferation assay
Real-Time cell kinetic analyzer xCELLigence RTCA
(ACEA Biosciences). was used to monitor the dynamic
changes of cell proliferation. Data analysis was performed
using RTCA Control Unit and the preinstalled RTCA soft-
ware. For real-time proliferation assay, E-plate 16 was
used. Cells were seeded directly onto E-plate. Changes in
baseline impedance resulting from the increase of cell
numbers were monitored by gold micro-electrodes lo-
cated at the bottom of E-plate. The proportional changes
in impedance were recorded continuously and expressed
as cell index (CI). Change of CI with time was monitored
continuously for 72 h.
Cell cycle analysis
Apoptosis was determined by propidium iodide (PI)
staining. Cells were harvested and fixed with 70 % etha-
nol for 24 h at 4 °C. The cells were stained with PI and
Table 1 Primers and probes for qPCR
Name Forward primer (5’-3’) Reverse primer (5’-3’) Probe numbera
BEX1 CACCTCGTGGCGAGAATC CTCTTTGGACTCCATTACTCCTG 63
BEX2 TCCTGAGGCTACGACCTTTC CGATTCTCGACGTGAGGTG 16
BEX3 CTTCGGTGCAGTCGTCACT ACACTTAGCCTCGCAGACCT 24
BEX4 GCCCCGAAATTAGGAAGC TGTTTGCCGCTAGTTCCTCT 15
BEX5 GCCGATTTCAAGGCTAAGAG GGACATTTTCCATGTTGAGTTTTT 34
RSAD2 CACGTAAACTAGATCAGGGAACAA TCAACAAACTGCATGGGATATT 55
S100A9 CTCCCACGAGAAGATGCAC GAGGCCTGGCTTATGGTG 81
IFI6 AACCGTTTACTCGCTGCTGT GGGCTCCGTCACTAGACCTT 40
PTPRZ1 GGCCTGTTGTCGTCCACT TCTGCTGCAACATACTGTCTAGC 67
MS4A4A GGAATTCTGCATTGCTGTGTC TGATGGCAGAATTAACACAACC 13
FABP5 GAGTGGGATGGGAAGGAAAG GATCCGAGTACAGGTGACATTG 22
S100A7 CCAAACACACACATCTCACTCA TCAGCTTGAGTGTTGCTCATC 33
S100A8 GCCAAGCCTAACCGCTATAA ATGATGCCCACGGACTTG 34
SPRR1B CAGAGTATTCCTCTCTTCACACCA CAAGGCTGTTTCACCTGCT 3
S100A12 CACATTCCTGTGCATTGAGG GGTGTCAAAATGCCCCTTC 31
S100A7A CATAGCCGCAGACTACCACA ACTGGCTTCCCCCAGAAC 21
SPRR1A AGCCCAAGGTTCCAGAGC TTCTGCTTGGTCTTCTGCTG 67
IFI44 AGCCTGTGAGGTCCAAGCTA GAACATCCTTTACAGGGTCCAG 6
PGLYRP3 CCCCACTCCCTTTGAGACT CTTGGCTGGTGAGGGTTG 3
IL1R1 GTCTCTGCTCTTGCCTCGAC TCAGCTAGAGAAAATGCGAGAA 63
CBX5 AGAAGATGAAGGAGGGTGAAAA GCGATATCATTGCTCTGCTCT 7
PTX3 TGTATGTGAATTTGGACAACGAA CATTCCGAGTGCTCCTGAC 58
PADI3 CAGCAATGACCTCAACGACA GAGGTAGAGCACCGCATAGG 19
ANKRD22 CAGTGCCTTTGTTTCATTGG CACCTGTCAGTGCTTTTCCA 74
LIF TGCCAATGCCCTCTTTATTC GTCCAGGTTGTTGGGGAAC 26
TMEM156 CATGGAATACCCGAATGATTG CCAAGTGATCTTCATGGAACAA 80
GPRC5B CCGCAGAGATGTGACTCG GATGCCACGAACATTCGAC 78
FTH1 GCCAGAACTACCACCAGGAC CATCATCGCGGTCAAAGTAG 1
SLC6A15 AAAGTGGGGGCTTAAACTGG CATAGCCAAGCAAACCATGA 27
SLITRK6 GAAGAAAAAGAAACTCAGGGATCA GGACAGACTAAATTGCCTGAAGA 7
PLLP CACCCGGCCTTATAACCAG AAGGCACTCACTCCATAGGC 9
aUniversal ProbeLibrary
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RNase A in PBS for 30 min in the dark. Cell-cycle distri-
bution was analyzed with a FACS flow cytometer (BD
Biosciences).
Animal models
Athymic nu/nu mice (5 weeks old, weight range: 18–
22 g) were used. CAL27 with pCDH-BEX4 vector or
empty vector pCDH were injected subcutaneously into
the right flank of mice. Four animals were used in each
group. Tumor growth was measured daily with calipers
in two dimensions. After 30 days, mice were euthanized.
The animals were maintained under pathogen-free con-
ditions with controlled temperature and humidity.
Microarray
Affymetrix whole-transcript expression microarray Hu-
man Exon 1.0 ST was used. All the RNA samples were
tested with Agilent 2100 Bioanalyser (Agilent Technolo-
gies). All the samples RNA had RIN value over 8. All the
tests were performed in the Centre for Genomic Sci-
ences, the University of Hong Kong. Data analysis was
evaluated using GeneSpring version 13 (Agilent Tech-
nologies). Genes with more than 1.5-fold difference and
p value below 0.01 were selected for qPCR validation.
Statistical analysis
Data were expressed as mean ± standard deviation. T-
test or Chi square test were used to compare difference
between groups as appropriate. Data analysis was per-
formed using SPSS® for Windows version 14.0 (SPSS,
Inc., Chicago, IL, USA). All the tests were two-sided. P-
values <0.05 were considered as statistically significant.
SurvExpress (Interface v2.0, Database Update: Sep 30,
2015) was used to perform survival analysis on oral can-
cer dataset GSE26549 as described [12]. The dataset
contains global gene expression data from 86 oral leuko-
plakia tissue samples examined with Affymetrix Human
Gene 1.0 ST Array [13].
Results
Aberrant expression of BEX4 in oral cancers
To identify the key BEX family members involved in
OSCC, we used qPCR to quantify BEX1-5 transcript
levels in 65 primary OSCC tissues and compared with
the paired normal epithelia. In comparison with the nor-
mal counterpart, expression of BEX1 (p < 0.001), BEX4
(p < 0.001) and BEX5 (p = 0.006) were significantly re-
duced in the OSCC tissues (Fig. 1a). In contrast, BEX3
expression showed significant elevation in OSCC (p =
0.026). For BEX2, no significant difference was observed
between the OSCC and paired normal tissues (p = 0.457).
The characteristics of the 65 patients examined were
shown in Table 2.
Low BEX4 expression was associated with poor outcome
in patients with oral pre-neoplastic lesions
We analyzed the association between BEX family mem-
ber expression and the outcome of 86 oral leukoplakia
patients from GSE26549 using SurvExpress. Low BEX4
expression was associated with poor cancer-free survival
of oral leukoplakia patients (Hazard ratio = 2.76, p =
0.0072) (Fig. 1b, c). The correlation of low BEX4 expres-
sion with poor cancer-free survival in leukoplakia pa-
tients was more significant than other BEX family
members including BEX1, BEX2, NGFRAP1 (BEX3) and
BEX5 (Fig. 1c).
Low BEX4 expression was associated with advanced
tumor stage
To confirm the specificity of BEX4 antibody, Western blot
was performed on the his-tagged recombinant human
BEX4 protein. Signal of the immunoreaction increased in
parallel with the concentration of recombinant BEX4
(Fig. 2a). In tissues obtained from OSCC patients, majority
of normal tissues (96.9 %) showed moderate or high ex-
pression of BEX4. In the OSCC tissues, low expression of
BEX4 was observed in 53.3 % tumor samples from pa-
tients with OSCC, while it was only found in 3.3 % paired
normal tissues (Fig. 2b). Moreover, 75 % tumor tissues
with T3-4 stage exhibited low BEX4 expression. In con-
trast, only 10 % tumor tissues with T1-2 stage displayed
low BEX4 expression (Table 3). Low BEX4 level was asso-
ciated with advanced stage tumor (p = 0.001, Table 3).
Representative images of BEX4 staining on oral tissues
were shown in Fig. 2c.
BEX4 was epigenetically silenced in OSCC
Next, we sought to examine whether DNA methylation
and histone acetylation are the major epigenetic alter-
ations leading to BEX4 suppression in OSCC. DNA
methylation was controlled by DNA methyltransferases
that catalyze the addition of a methyl group to DNA.
Zebularine inhibited DNA methyltransferases through
the formation of a covalent complex with them [14].
Histone deacetylases (HDACs) catalyze the removal of
acetyl groups of histone, leading to chromatin con-
densation and transcriptional suppression. TSA was a
specific inhibitor of HDAC activity [15]. Following treat-
ment with zebularine and TSA, dose-depending increase
in BEX4 expression was observed in CAL27 cells (Fig. 3).
The protein expression level of BEX4 was also enhanced
following zebularine and TSA treatment (Fig. 3).
BEX4 reduced the proliferation and tumor growth of OSCC
Having established that BEX4 expression was suppressed in
OSCC, we hypothesized that BEX4 has a tumor
suppressing function in OSCC. We generated BEX4-
overexpressing OSCC cell lines (Fig. 4a–c) and measured
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the change of proliferation rate. BEX4-overexpressing
cells showed significant reduction in OSCC proliferation
(Fig. 4d, e). Apoptotic cells were determined by PI staining
using flow cytometry. Flow cytometry analysis showed
that BEX4 overexpression in OSCC did not induce apop-
tosis of OSCC (Fig. 4f). To confirm our results, two differ-
ent BEX4-specific siRNAs were used to silence the
expression of BEX4 in OSCC cells (Fig. 5a, b). Silence of
BEX4 resulted in a significant increase in the proliferation
of CAL27 and YD-38 cells (Fig. 5c, d).
In the animal model, BEX4-overexpressing xenograft
developed from CAL27 cells had a significantly smaller
tumor volume and slower growth rate (Fig. 6). Tumor
volume of control xenograft increased by 4.7-fold from
day 17 to day 53. In contrast, tumor volume of BEX4-
overexpressing xenograft increased by only 1.7-fold
(Fig. 6). The data is consistent with the cell line models
suggesting that BEX4 was involved in controlling OSCC
growth.
S100A family is the potential downstream targets
regulated by BEX4
As there is no sufficient information about the regulatory
mechanisms of BEX4 in human diseases, we used
Table 2 Association of BEX4 mRNA expression level with the
clinicopathological variables in 65 patients with OSCC
Variables Cases BEX4 expression P value*
Low (%) High (%)
Gender - - - 0.875
Male 40 20 (50) 20 (50) -
Female 25 13 (52) 12 (48) -
Age - - - 0.708
> 59 32 17 (53) 15 (47) -
≤ 59 33 16 (48) 17 (52) -
T-stage - - - 0.174
T1-2 29 12 (41) 17 (59) -
T3-4 36 21 (58) 15 (42) -
Nodal stage - - - 0.694
Negative 37 18 (49) 19 (51) -
Positive 28 15 (54) 13 (46) -
*Pearson chi-square test
Fig. 1 Expression of BEX family members in OSCC. a Boxplots showing expression level of BEX family members in OSCC and paired normal
tissues. Each sample were normalized to GAPDH and displayed using 2-ΔCt values. b Cox survival analysis of cancer-free survival was performed
on oral leukoplakia patients based on the BEX4 expression expression level. c Boxplots showing the expression level of BEX family members in
different risk group
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microarray to explore the global gene expression changes
in BEX4-overexpressing OSCC cell line CAL27. Twenty-
six genes showed differential expression (Table 4). The fil-
tered genes were then validated in BEX4-overexpressing
Cal27 and YD-38 again. Of which, the expression patterns
of 16 genes were consistent with the microarray results
(Fig. 7). According to the expression patterns in qPCR
results, we classified the genes into BEX4-suppressed
genes (S100A7, S100A8, S100A7A, RSAD2, S100A12,
SPRR1B, S100A9, SPRR1A, MS4A4A, IF16, PGLYRP3,
IL1R1, IFI44, FABP5, PTPRZ1) and BEX4-induced genes
(FTH1, PLLP, SLC6A15, PTX3, CBX5, TMEM156,
GPRC5B, ANKRD22, LIF, PADI3, SLITRK6). Among the
differentially expressed genes, expression changes of mul-
tiple S100A family members were observed in BEX4-
overexpressing Cal27 and YD-38. S100A7, S100A7A,
S100A8, S100A9 and S100A12 were remarkably increased
in the BEX4-overexpressing OSCC cell lines.
Discussion
Our results indicated that BEX4 functions as tumor sup-
pressor in controlling proliferation and growth of OSCC.
At present, little is known about the expression status
and functions of brain expressed X-linked family in
OSCC. Thus, we first examined the mRNA levels of
BEX1, BEX2, BEX3, BEX4 and BEX5 in our OSCC tis-
sues and compared with the paired normal epithelia. We
identified that BEX4 suppression is a common event in
our OSCC and is potentially associated with the poor
outcome of patients. The association between low BEX4
with poor outcome of patients with oral pre-neoplastic
lesions suggested that reduced BEX4 is an early event in
the development of OSCC.
OSCC is a male dominant disease. Recent epidemi-
ology study revealed that there is an increasing number
of female OSCC cases [16]. In our cohort, reduced
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Fig. 2 Immunohistochemical analysis of BEX4 expression in OSCC. In total, 30 paired tumor and normal tissues from patients with OSCC.
a Specificity of BEX4 antibody. Western bot analysis showed that the anti-human BEX4 antibody can specifically detect the recombinant human
BEX4 protein. b Distribution of tissue BEX4 expression level in our OSCC cohort. c Representative immunohistochemical staining images showing
BEX4 expression on OSCC tissues and paired normal epithelia
Table 3 Association of BEX4 protein expression level with the
clinicopathological variables in 30 patients with OSCC
Variables Cases BEX4 expression P value
Low (%) Moderate + High (%)
Gender - - - 0.796a
Male 20 11 (55) 9 (45) -
Female 10 5 (50) 5 (50) -
Age - - - 0.464a
≤54 15 9 (60) 6 (40) -
>54 15 7 (47) 8 (53) -
T-stage - - - 0.001b
T1-2 10 1 (10) 9 (90) -
T3-4 20 15 (75) 5 (25) -
Nodal stage - - - 0.464a
Negative 15 7 (47) 8 (53) -
Positive 15 9 (60) 6 (40) -
aPearson chi-square test; bFisher’s exact test; Bold data indicated
statistically significant
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Fig. 3 Epigenetic drugs induced BEX4 expression in OSCC. a Zebularine and TSA treatment upregulated BEX4 expression in OSCC cell lines.
b Immunostaining analysis showed that BEX4 protein increased in CAL27 and YD-38 after zebularine and TSA treatment
Fig. 4 Effect of BEX4 overexpression on OSCC proliferation. a pCDH-BEX4 containing OSCC cells showed positive GFP signals. b QPCR analysis showed
remarkable increase in BEX4 transcript levels. c Western blot analysis showed increase in protein expression in the infected cells. d Upregulated BEX4
expression in OSCC inhibited cell proliferation. e Time-dependent reduction in proliferation capacity of the BEX4-overexpressed OSCC. f Flow cytometry
analysis with PI staining showed that BEX4 expression did not induce apoptosis in the OSCC cells
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BEX4 expression is also observed in the female group.
Functional analysis revealed that BEX4 reduced prolifer-
ation propensity of OSCC. The remarkable reduction of
xenograft volume further supports our suggestion that
BEX4 controls the proliferative growth process of OSCC.
Taken together, our results provide evidence showing a
putative tumor-suppressing functions of BEX4 in OSCC.
Members of BEX family have been implicated in regu-
lating apoptosis in various human cancer cells and
normal cells. In breast cancer, BEX2 could modulate
ceramide-induced apoptosis via protein phosphatase 2A
[17, 18]. BEX1 interacted with B-cell lymphoma 2 (BCL-
2) and inhibited the formation of BCL-2/BCL-2-associated
X protein (BAX) complex, leading to enhancement of
imatinib-induced apoptosis in human leukemic cell line
K562 [19]. BEX3 could interact with the death domain of
p75 neurotrophin receptor (p75NTR) and induce apop-
tosis upon nerve growth factor (NGF) treatment in
HEK293 cells [20]. In light of the regulating role of BEX
family in apoptosis, we investigated whether BEX4
Fig. 5 Effect of BEX4 knockdown on OSCC proliferation. a OSCC transfected with 2 different BEX4-specific siRNAs showed significant reduction in
endogenous BEX4 transcript levels. b Immunostaining indicated BEX4 protein reduction in OSCC transfected with BEX4 siRNAs. c Knockdown
BEX4 with siRNA promoted OSCC proliferation. d Time-dependent increase in proliferation capacity of BEX4 knockdown OSCC
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Fig. 6 BEX4 inhibited growth of CAL27 xenograft. a Xenograft growth curve. b Xenograft excised from the indicated time point
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overexpression affect apoptosis in OSCC. Unlike other
BEX family proteins, BEX4 had no inducing effect on
apoptosis and cell cycle arrest.
At present, the functional roles of BEX family mem-
bers in cancer remain unclear. In OSCC, it has been re-
ported that BEX1 is involved in modulating nuclear
factor-κB (NF-κB) signaling pathway [8]. BEX2 ex-
pression could possibly be modulated by the aberrantly
activated mechanistic target of rapamycin (mTOR) in
cancer cells [21]. BEX protein family is also known as in-
trinsically disordered proteins (IDPs), which exist as dy-
namic ensemble of conformation with no discrete 3D
structure. IDPs are suggested to play an important role
in tumorigenesis and are involved in modulating mul-
tiple gene regulating signaling pathways by their ability
to recognize multiple interaction partners [22]. Our re-
sults revealed that BEX family member, BEX4, is one of
the IDP involved in the pathogenesis of OSCC.
Epigenetic silencing of tumor suppressor gene is a
characteristic feature of OSCC. Existing data suggests
that DNA methylation and chromatin remodeling play
an important role in modulating BEX family expression
in human malignancies [23, 24]. In glioma, BEX1 and
BEX2 are silenced and the expression could be activated
by treatment with DNA methyltransferase inhibitor and
histone deacetylase inhibitor [25]. Our results are con-
sistent with the current knowledge suggesting that BEX4
is epigenetically silenced in OSCC.
OSCC overexpressing BEX4 showed significant up-
regulation of S100A family members (S100A7, S100A8,
S100A9, S100A12, S100A15 or S100A7A). S100A is a
family of calcium binding protein involved in multiple
processes of cancer development [26]. Of which, S100A7
dysregulation is believed to be involved in a wide range
of pathological processes associated with OSCC. S100A7
(also known as psoriasin) was expressed in early stage
oral cancer. S100A7 expression was reduced in tumor in
late stage [27]. Additionally, highly differentiated OSCC
usually had high expression of S100A7 as compared to
the moderate or poorly differentiated counterparts [28].
Table 4 Gene expression profile of BEX4-overexpressing CAL27
Transcripts cluster Id Gene symbol Regulation Fold-change Gene name
2436051 S100A7 Up 3.03 S100 Calcium Binding Protein A7
2435989 S100A8 Up 2.80 S100 Calcium Binding Protein A8
2359691 S100A7A Up 2.47 S100 Calcium Binding Protein A7A
2468351 RSAD2 Up 2.00 Radical S-Adenosyl Methionine Domain Containing 2
2435981 S100A12 Up 1.79 S100 Calcium Binding Protein A12
2359521 SPRR1B Up 1.79 Small Proline-Rich Protein 1B
2359664 S100A9 Up 1.72 S100 Calcium Binding Protein A9
2359492 SPRR1A Up 1.68 Small Proline-Rich Protein 1A
3332298 MS4A4A Up 1.65 Membrane-Spanning 4-Domains, Subfamily A, Member 4A
2403261 IFI6 Up 1.64 Interferon, Alpha-Inducible Protein 6
2435949 PGLYRP3 Up 1.59 Peptidoglycan Recognition Protein 3
2496962 IL1R1 Up 1.58 Interleukin 1 Receptor, Type I
2343511 IFI44 Up 1.56 Interferon-Induced Protein 44
3104933 FABP5 Up 1.54 Fatty Acid Binding Protein 5 (Psoriasis-Associated)
3021377 PTPRZ1 Up 1.52 Protein Tyrosine Phosphatase, Receptor-Type, Z Polypeptide 1
4037708 FTH1 Down 2.39 Ferritin, Heavy Polypeptide 1
3693141 PLLP Down 1.67 Plasmolipin
3464276 SLC6A15 Down 1.61 Solute Carrier Family 6 (Neutral Amino Acid Transporter), Member 15
2649367 PTX3 Down 1.60 Pentraxin 3, Long
3456630 CBX5 Down 1.59 Chromobox Homolog 5
2766289 TMEM156 Down 1.54 Transmembrane Protein 156
3683377 GPRC5B Down 1.54 G Protein-Coupled Receptor, Class C, Group 5, Member B
3299469 ANKRD22 Down 1.54 Ankyrin Repeat Domain 22
3957160 LIF Down 1.54 Leukemia Inhibitory Factor
2322818 PADI3 Down 1.52 Peptidyl Arginine Deiminase, Type III
3519840 SLITRK6 Down 1.51 SLIT And NTRK-Like Family, Member 6
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Forced expression of S100A7 is accompanied by repressed
cell proliferation and tumor progression in orthotopic
tongue tumor model [27].
Apart from S100A7, aberrant expression of other S100A
family members is emerging as an important event in
head and neck cancers. In head and neck squamous cell
carcinoma, S100A8/A9 (calprotectin) could suppress cell
growth by inducing G2/M cell cycle checkpoint arrest
[29]. The mRNA and protein expression levels of S100A8/
A9 are decreased in head and neck cancers. S100A8/A9
can modulate G2/M Cdc2/cyclin B1 complex activation
resulting in G2/M checkpoint arrest [29]. For S100A12,
high level in tumor tissue is a good prognostic indicator
for oropharyngeal squamous cell carcinoma patient [30].
S100A7A (koebnerisin) are highly homologous to S100A7.
Both S100A7A and S100A7 could serve as oncogenic in-
activator in human malignancies [31].
The molecular mechanisms underlying S100A proteins
dysregulation remains unclear. In OSCC, it has been
shown that overexpression of β-catenin decreased the
expression of S100A7, while silence of β-catenin en-
hanced its expression, indicating that β-catenin signaling
negatively modulated S100A7 [27]. In addition, c-Myc
suppressed S100A7 expression by directly binding to its
promoter [32].
Conclusions
Based on the current results, we suggested that BEX4
controls OSCC proliferation. Although the mechanisms
underlying BEX4 suppression in OSCC remains unre-
solved, induced expression of BEX4 in the presence of
epigenetic drugs suggested that BEX4 is epigenetically si-
lenced in OSCC. Taken together, we suggested that
BEX4 functions as a novel tumor suppressor gene in-
volved in OSCC.
Abbreviations
BAX: BCL-2-associated X protein; BCL-2: B-cell lymphoma 2; BEX: brain-
expressed X-linked; HDACs: histone deacetylases; HNSCC: head and neck
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Fig. 7 Gene expression changes in BEX4-overexpressing CAL27. Global gene expression changes were evaluated using Affymetrix Human Exon
1.0 ST. The differential expressed genes were further evaluated in BEX4-overexpressing OSCC cell lines. a Gene up-regulated in BEX4-overexpressing
CAL27 and YD-38. b Gene down-regulated in BEX4-overexpressing CAL27 and YD-38
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